Literature DB >> 1632458

Interleukin-6, but not interleukin-4, is expressed by Reed-Sternberg cells in Hodgkin's disease with or without histologic features of Castleman's disease.

S M Hsu1, S S Xie, P L Hsu, J A Waldron.   

Abstract

Hodgkin's disease (HD) is a neoplastic disease that is characterized by unbalanced and/or unregulated cytokine production. Information accumulated in our own and other laboratories indicates that the cytokines interleukin-1 (IL-1), IL-5, IL-9, tumor necrosis factor-alpha (TNF-alpha), granulocyte colony-stimulating factor (G-CSF), macrophage CSF (M-CSF), and transforming growth factor-beta (TGF-beta) are secreted by Hodgkin's and Reed-Sternberg (H-RS) cells. These and perhaps additional cytokines are likely to be responsible for the unique histopathologic and clinical alterations seen in patients with HD. In this study, we confirmed that IL-6 is produced by cultured H-RS cells as well as by H-RS cells in tissues. By using an enzyme-linked immunosorbent assay, we found that approximately 2 to 10 ng/ml of IL-6 was secreted by cultured H-RS cells (10(6) cells/ml). In tissues, we were able to immunolocalize IL-6 in the cytoplasm in 10 to 30% of H-RS cells by using rabbit polyclonal and mouse monoclonal anti-IL-6 antibodies. There was no correlation among the IL-6 staining intensity, number of H-RS cells stained, and the degree of plasma cell infiltration. However, in 3 of 17 cases studied, a large number (60%) of H-RS cells were positive for IL-6, and in these patients, abundant plasma cells were present. In one patient, the involved lymph node also showed histologic features similar to those of Castleman's disease. In this patient, we noted abundant IL-6 expression not only in H-RS cells, but also in most reactive histiocytes. The cultured H-RS cells did not express functional receptors for IL-6, and exogenously added IL-6 did not induce proliferation of these cells. We also conducted studies with specific anti-IL-4 antibodies, which did not show IL-4 production by H-RS cells in both cultures and tissues. In tissues, only rare IL-4 positive lymphoid cells or dendritic cells were identified. Thus, the study demonstrated that adequate amounts of IL-6 are required for an abundant plasma cell reaction, and that an additional source of IL-6 from histiocytes is essential for the formation of Castleman's disease-like changes in lymph nodes involved by HD. Furthermore, IL-4 is not likely to be responsible for the T-lymphocyte reaction in tissues, by a mechanism distinct from that in T-cell-rich B-cell lymphomas.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1632458      PMCID: PMC1886582     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  55 in total

Review 1.  Interleukin-6: historical background, genetics and biological significance.

Authors:  M C Wolvekamp; R L Marquet
Journal:  Immunol Lett       Date:  1990 Mar-Apr       Impact factor: 3.685

2.  Simultaneous production of IL-2, IL-4, and IFN-gamma by activated human CD4+ and CD8+ T cell clones.

Authors:  X Paliard; R de Waal Malefijt; H Yssel; D Blanchard; I Chrétien; J Abrams; J de Vries; H Spits
Journal:  J Immunol       Date:  1988-08-01       Impact factor: 5.422

3.  Lack of effect of colony-stimulating factors, interleukins, interferons, and tumor necrosis factor on the growth and differentiation of cultured Reed-Sternberg cells. Comparison with effects of phorbol ester and retinoic acid.

Authors:  S M Hsu; P L Hsu
Journal:  Am J Pathol       Date:  1990-01       Impact factor: 4.307

4.  AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6.

Authors:  S A Miles; A R Rezai; J F Salazar-González; M Vander Meyden; R H Stevens; D M Logan; R T Mitsuyasu; T Taga; T Hirano; T Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

5.  Cytochemical, immunologic, chromosomal, and molecular genetic analysis of a novel cell line derived from Hodgkin's disease.

Authors:  H Kamesaki; S Fukuhara; E Tatsumi; H Uchino; H Yamabe; H Miwa; S Shirakawa; M Hatanaka; T Honjo
Journal:  Blood       Date:  1986-07       Impact factor: 22.113

6.  Expression of the macrophage growth factor, CSF-1 and its receptor c-fms by a Hodgkin's disease-derived cell line and its variants.

Authors:  E Paietta; J Racevskis; E R Stanley; M Andreeff; P Papenhausen; P H Wiernik
Journal:  Cancer Res       Date:  1990-04-01       Impact factor: 12.701

7.  Human granulocyte-macrophage colony-stimulating factor purified from a Hodgkin's tumor cell line.

Authors:  P V Byrne; W F Heit; C J March
Journal:  Biochim Biophys Acta       Date:  1986-12-12

8.  Phenotypic expression of Hodgkin's and Reed-Sternberg cells in Hodgkin's disease.

Authors:  S M Hsu; K Yang; E S Jaffe
Journal:  Am J Pathol       Date:  1985-02       Impact factor: 4.307

9.  Synergistic activation of human T cells by interleukin 1 and interleukin 6.

Authors:  F A Houssiau; P G Coulie; D Olive; J Van Snick
Journal:  Eur J Immunol       Date:  1988-04       Impact factor: 5.532

10.  Neoplastic cells obtained from Hodgkin's disease are potent stimulators of human primary mixed lymphocyte cultures.

Authors:  R I Fisher; F Bostick-Bruton; D N Sauder; G Scala; V Diehl
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

View more
  10 in total

1.  Acute liver failure secondary to hepatic infiltration: a single centre experience of 18 cases.

Authors:  D Rowbotham; J Wendon; R Williams
Journal:  Gut       Date:  1998-04       Impact factor: 23.059

2.  CD137 signaling in Hodgkin and Reed-Sternberg cell lines induces IL-13 secretion, immune deviation and enhanced growth.

Authors:  Sakthi Rajendran; Weng Tong Ho; Herbert Schwarz
Journal:  Oncoimmunology       Date:  2016-04-29       Impact factor: 8.110

Review 3.  Hodgkin's lymphoma: the pathologist's viewpoint.

Authors:  S A Pileri; S Ascani; L Leoncini; E Sabattini; P L Zinzani; P P Piccaluga; A Pileri; M Giunti; B Falini; G B Bolis; H Stein
Journal:  J Clin Pathol       Date:  2002-03       Impact factor: 3.411

Review 4.  Acute liver failure due to lymphoma. A diagnostic concern when considering liver transplantation.

Authors:  G M Woolf; L M Petrovic; S E Rojter; F G Villamil; L Makowka; L G Podesta; L S Sher; L Memsic; J M Vierling
Journal:  Dig Dis Sci       Date:  1994-06       Impact factor: 3.199

5.  Three patients with both Hodgkin's lymphoma and Castleman's disease: Clinicopathologic correlations and lack of association with HHV-8.

Authors:  Saadiya Haque; Robert van Kirk
Journal:  Indian J Med Paediatr Oncol       Date:  2009-04

6.  IL-6-positive classical Hodgkin's lymphoma co-occurring with plasma cell type of Castleman's disease: report of a case.

Authors:  Akihito Momoi; Masaru Kojima; Takeshi Sakai; Junya Ajiro; Noriatsu Isahai; Kouichi Nagai; Sadao Aoki
Journal:  Int J Hematol       Date:  2013-01-29       Impact factor: 2.490

7.  Functional heterogeneity and pathogenic significance of interleukin-6 in B-cell lymphomas.

Authors:  S M Hsu; S S Xie; J A Waldron
Journal:  Am J Pathol       Date:  1992-10       Impact factor: 4.307

8.  Pathobiology of hodgkin lymphoma.

Authors:  Pier Paolo Piccaluga; Claudio Agostinelli; Anna Gazzola; Claudio Tripodo; Francesco Bacci; Elena Sabattini; Maria Teresa Sista; Claudia Mannu; Maria Rosaria Sapienza; Maura Rossi; Maria Antonella Laginestra; Carlo A Sagramoso-Sacchetti; Simona Righi; Stefano A Pileri
Journal:  Adv Hematol       Date:  2010-12-22

9.  Coexistence of Hodgkin's Lymphoma and Castleman's Disease: A Case Report with Successful Response to Chemotherapy and Radiotherapy.

Authors:  Amina Mohtaram; Mohammed Afif; Tanae Sghiri; Amal Rami; Rachida Latib; Fouad Kettani; Meryam Ben Ameur El Youbi; Saber Boutayeb; Tayeb Kebdani; Noureddine Benjaafar; Imane Aaribi; Hassan Errihani
Journal:  Case Rep Oncol Med       Date:  2013-12-05

10.  Fulminate hepatic failure as an initial presentation of non-hodgkin lymphoma: a case report.

Authors:  Bizhan Ahmadi; Sara Shafieipour; Kambiz Akhavan Rezayat
Journal:  Middle East J Dig Dis       Date:  2014-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.